1. Histological Analysis in ABO-Compatible and ABO-Incompatible Kidney Transplantation by Performance of 3- and 12-Month Protocol Biopsies
- Author
-
Kazunari Tanabe, Kosuke Masutani, Akihiro Tsuchimoto, Kazuhiko Tsuruya, Yasuhiro Okabe, Masayoshi Okumi, Hidehisa Kitada, Masafumi Nakamura, Kei Kurihara, and Takanari Kitazono
- Subjects
Graft Rejection ,Male ,Time Factors ,Biopsy ,medicine.medical_treatment ,030232 urology & nephrology ,030230 surgery ,Kidney ,Gastroenterology ,0302 clinical medicine ,Japan ,hemic and lymphatic diseases ,Living Donors ,Cumulative incidence ,Kidney transplantation ,Subclinical infection ,medicine.diagnostic_test ,Histocompatibility Testing ,Incidence ,Graft Survival ,Plasmapheresis ,Middle Aged ,Treatment Outcome ,Blood Group Incompatibility ,Histocompatibility ,Female ,Rituximab ,Immunosuppressive Agents ,medicine.drug ,Adult ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Opportunistic Infections ,ABO Blood-Group System ,Nephropathy ,Immunocompromised Host ,03 medical and health sciences ,Predictive Value of Tests ,Internal medicine ,ABO blood group system ,parasitic diseases ,medicine ,Humans ,Retrospective Studies ,Transplantation ,business.industry ,medicine.disease ,Kidney Transplantation ,biological factors ,Surgery ,business - Abstract
ABO-incompatible (ABO-I) kidney transplantation (KTx) is an established procedure to expand living donor sources. Although graft and patient survival rates are comparable between ABO-compatible (ABO-C) and ABO-I KTx, several studies have suggested that ABO-I KTx is associated with infection. Additionally, the histological findings and incidence of antibody-mediated rejection under desensitization with rituximab and plasmapheresis remain unclear. We reviewed 327 patients who underwent living-donor KTx without preformed donor-specific antibodies (ABO-C, n = 226; ABO-I, n = 101). Patients who underwent ABO-I KTx received 200 mg/body of rituximab and plasmapheresis, and protocol biopsy (PB) was planned at 3 and 12 months. We compared the PB findings, cumulative incidence of acute rejection in both PBs and indication biopsies, infection, and patient and graft survivals. The 3- and 12-month PBs were performed in 85.0% and 79.2% of the patients, respectively. Subclinical acute rejection occurred in 6.9% and 9.9% of patients in the ABO-C and ABO-I groups at 3 months (P = 0.4) and in 12.4% and 10.1% at 12 months, respectively (P = 0.5). The cumulative incidence of acute rejection determined by both PBs and indication biopsies was 20.5% and 19.6%, respectively (P = 0.8). The degrees of microvascular inflammation and interstitial fibrosis/tubular atrophy were comparable. Polyomavirus BK nephropathy was found in 2.7% and 3.0% of patients in the ABO-C and ABO-I groups, respectively (P = 1.0). The incidence of other infections and the graft/patient survival rates were not different. Analyses using 3- and 12-month PBs suggested comparable allograft pathology between ABO-C and ABO-I KTx under desensitization with low-dose rituximab and plasmapheresis.
- Published
- 2017